Product Description
pegylated recombinant human arginase for children and young people with relapsed/refractory leukaemia, neuroblastoma, sarcoma and high grade gliomas (brain cancers). (Sourced from: https://clinicaltrials.gov/ct2/show/NCT03455140)
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Coagulation Factor
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Bio-Cancer Treatment International Limited
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Acute Myeloid Leukemia|Hepatocellular Carcinoma|Leukemia|Neuroblastoma|Sarcoma|Brain Cancer|Glioma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| PARC | P2 |
Completed |
Brain Cancer|Glioma|Neuroblastoma|Sarcoma|Leukemia |
2022-07-22 |
2022-09-03 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
|
| PARC | P2 |
Unknown status |
Sarcoma|Leukemia|Glioma|Neuroblastoma|Brain Cancer |
2021-05-01 |
2022-03-13 |
Treatments |
|
| BCT-100-007 | P2 |
Unknown status |
Acute Myeloid Leukemia |
2019-09-01 |
2020-03-11 |
Primary Endpoints|Treatments|Trial Status |
|
| BCT-100-006 | P2 |
Completed |
Hepatocellular Carcinoma |
2017-03-01 |
2021-08-11 |
Primary Endpoints |